State ID: Date	of Incident Specimen Co	llection (<i>mm-a</i>	ld-yyyy):	Surveillance	Officer Initials
Form Approved OMB No. 092-0978	CANDIDEM	IA 2022 CASI	E REPORT FOR	M	
Patient name:(Last, First	+ MT)		Medical Record No	o.:	
Address:	., MI)		Hospital:		
(Number, Street, Apt. No.)				isolate):	
			•		
(City, State)	(Zip Code)		ACC NO. (SUDSEQ IS	solate):	
Address type: 1 Residential 2 Post office 3	Long-term care facility 4	Corrections	5 Military 6]Homeless 7 🗌 Other 8 [Insufficient 9 Missing
Phone no.: ()					
Check if not a case: 🗌					
Reason not a case: Out of catch	nment area 🔲 Duplicate en	try 🗌 Not candi	demia 🗌 Unable	o verify address 🗌 Other (specify):
SURVEILLANCE OFFICER INFO	RMATION				
1. Date reported to EIP site:	3. Was case first identified through audit	5. Previous o	candidemia epis	ode?	6. CRF status: 7. SO
	1 \square Yes 0 \square No				
		5a. If yes, ent	er state		2 Pending
2. Date review completed:	4. Isolate available?	IDs:			3 Chart
	1 🗌 Yes 0 🗌 No				unavailable
DEMOGRAPHICS					
8. State ID:	10. State:		11. Co	unty:	
9. Patient ID:					
12. Lab ID where positive culture	e was identified:				
13. Date of birth (<i>mm-dd-yyyy</i>):	14. Age:			15. Sex:	
		1 🗌 days 2 🗌 m	ios 3 Ovrs	□ Male □ Female □	Check if transgender
	17. Height:			18. BMI: (record only i	
lbs oz. Of		t in	. OR	available)	
kg Unknown					_ Unknown
				20 Ethnic origin:	
19. Race (check all that apply):		iian/Dacific Island	dor	20. Ethnic origin: 1 Hispanic/Latino	
American Indian/Alaska Native		iian/Pacific Island	Jer		
	White			2 Not Hispanic/Latino	
Black/African American				9 🗌 Unknown	
LABORATORY DATA					
21. Date of Incident Specimen C	ollection (DISC) (mm-dd-	· <i>yyyy</i>):			
22. Location of Specimen Collect	ion:				
	_			LTCF	
Hospital Inpatient Facility ID:	Uutpatient Facility ID:			Facility ID:	
	Emergency Roor			LTACH	
Surgery/OR				Facility ID:	
□ Radiology				Autopsy	
Other inpatient	Surgery			Other (specify):	
	Observational/cl	inical decision ur	_	Unknown	
	Other outpatient	t			
23. Incident Specimen Collection	ı Site	24. <i>Candida</i> s	pecies from init	ial positive blood culture	(check all that apply):
(check all that apply):					
Dublis assessments a busides of the U.S. C. C. C.			- Harris Francis		
Public reporting burden of this collection of informatic needed, and completing and reviewing the collection					
number. Send comments regarding this burden estima 74, Atlanta, Georgia 30329; ATTN: PRA (0920-0978).	ate or any other aspect of this collection	of information, includin	g suggestions for reducing	this burden to CDC/ATSDR Reports Clea	rance Officer; 1600 Clifton Road NE, N

State II	D:	_ Date o	f Incide	nt Speci	imen Co	ollection	n (<i>mm-</i>	dd-yyyy	v):·	·	s	urvei	llance	Officer	Initials			
	d, Central Line d, Peripheral stick d, not specified r (specify): own			☐ Candida ☐ Candida ☐ Candida ☐ Candida ☐ Candida ☐ Candida			ndida gla ndida pa ndida tro ndida du	abrata (C prapsilosi ppicalis (pbliniensi	CG) <i>is</i> (CP) CT) <i>is</i> (CD)	Candida, germ tube negative/non albicans (CG				 CGN)				
25. Anti	ifungal susceptibi	lity testi	ng (chec	k here [if no	testing	done/	no test	reports	availab	le):							
	Date of culture	Spe	cies		Drug	J		MIC			I	nterp	retatio	on				
				A	mphoter	icin B				□s	SDD	Π	□R	□NI				
		1 □CA 2 □CG		Anidu	ulafungir	ı (Eraxis)			□s	SDD	Π	□R	□NI				
		3 □СР		Caspo	ofungin (Cancidas	5)			□s	SDD	ΠI	□R	□NI				
		4 □CT 5 □CD		Fluco	nazole (Diflucan)			□s	SDD	ΠI	□R	□NI				
		6 □CL 7 □CK		Flu	icytosine	(5FC)				□s	□SDD	ΠI	□r	□NI				
		8 □CG 9 □CO	М	Itraco	nazole (Sporano	x)			□s		Π	□R	□NI				
		10 🗌 CG		Micaf	ungin (M	lycamine	e)			□s		Π	□R	□NI				
		11 □CS 12 □Per	nding	Posad	conazole	(Noxafi	l)			□s		Π	□R	□NI				
				Vorio	conazole	(Vfend)				□s		Π	□R	□NI				
				A	mphoter	icin B				□s	□sdd	ΠI	□r	□ni				
		1 🗌 CA		Anidu	ulafungir	ı (Eraxis)			□s	SDD	ΠI	□r	□NI				
			□CG □CP		fungin (Cancidas	5)			□s	□sdd	ΠI	□r	□NI				
				5 🗌 CD 5 🔲 CL	Fluco	nazole (Diflucan)			□s	□sdd	ΠI	□r	□NI			
		6 □CL 7 □CK			Flu	icytosine	e (5FC)				□s	□sdd	ΠI	□r	□NI			
		8 □CG	CGM		nazole (Sporano	x)			□s	□SDD	ΠI	□r	□NI				
		9 □CO 10 □CGN		Micaf	ungin (M	lycamine	e)			□s	□SDD	ΠI	□r	□NI				
		11 □CS 12 □Per	nding	Posad	conazole	(Noxafi	I)			□s	□SDD	ΠI	□r	□NI				
				Vorio	conazole	(Vfend)				□s	□SDD	ΠI	□r	□NI				
26 Anv	subsequent posit	tive Can	<i>lida</i> bloo	d cultu	res in tl	ne 29 da	avs afte	r noti	ncludin	a the Di	ISC? 1		s 0 []No 9[
_	es, provide dates of						-	-		-								
Date Dr	awn (<i>mm-dd-yyyy</i>))	Specie	s identif	fied*													
			□CA	□cg	□ср	□ст	□cd	□cl	□ск		1 □co	:			□cs	ΠÞ	ending	
			□CA	□cg	ПСЬ	□ст	□cd	□CL	□ск		1 □co	:			□cs	□P ^r	ending	
			□CA	□cg	ПСЬ	□ст		□CL	□ск		1 □co	:			□cs	□ Pr	ending	
				□cg	ПСЬ	□ст									□cs	ΠP	ending	
*Attach	additional MIC page	e if addi	_														5	
	andida species (if n							igiliai),		ner <i>e, gl</i>	<i>ubi ata</i> (6	.ven 11	ongin	iai was C	. yiavi d			
27. Doc negativ	umented negative e culture were po	e <i>Candid</i> sitive in	a blood of the 29 d	culture ays afte	on the o er the D	day of c ISC)?	or in the 1 □Yes	e 29 day 0 □ N	/s after o 9□	the DIS Unknowr	i C (in wi	nich n	o bloc	od cultu	res aftei	' this		

State ID: Dat	e of Incident Specimen	Collection (<i>mm-dd-yyyy</i>):	Surveillance Officer Initials
27a. If yes, date of negative blood	culture:		
	sistant organism (MDR		lonized with or being managed as if they were ns)? MDROs include CRE, CRPA, CRAB, MRSA, and VRE.
28a. If yes, specify organisms (Ent	er up to 3 pathogens):	//	
			r in the 6 days before the DISC:
1 🗌 Yes 0 🗌 No 9 🗌 Unkno	wn		
29a. If yes, additional organisms (Enter up to 3 pathogens):	//	
30. Infection with <i>Clostridioide</i>	es difficile <u>on the day of</u>	f or in the 89 days before or 2	<u>9 days after</u> the DISC:
1 🗌 Yes 0 🗌 No 9 🗌]Unknown		
30a. If yes, date of first <i>C. diff</i> diag	nosis:	U	nknown
31. Did the patient have any of None Unknown	f the following types of	infection/colonization relate	d to their <i>Candida</i> infection? (check all that apply):
Abdominal	Candiduria	Pulmonary	Endocarditis
Hepatobiliary or pancreatic	Esophagitis	Abscess	Septic emboli (specify location):
□GI tract	Oral/thrush	Respiratory specimen with	Candida Other (specify):
Abscess (specify):	Osteomyelitis	CNS involvement (meningitis	, brain
Peritonitis/peritoneal fluid	Skin lesions/wounds	abscess)	
		Eyes (endophthalmitis or cho	rioretinitis)
MEDICAL ENCOUNTERS			
32. Was the patient hospitalize	ed on the day of or in th	e 6 days after the DISC?	1 🗌 Yes 0 🗌 No 9 🗌 Unknown
32a. If yes, Date of first admission:		Unknown	
Hospital ID:		vn	
32b. Was the patient transferred of 1 Types 0 No 9 Unkn			
If yes, enter up to two transfers:			
Date of transfer:	[] Unknown Date of second tra	ansfer: 🔲 Unknown
Hospital ID:	Unknown	Hospital ID:	Unknown
32c. Where was the patient locate DISC? (<i>Check one</i>)	ed prior to admission or,	if not hospitalized, where was	the patient located on the 3rd calendar day before the
1 Private residence	4 🗌 LTA	СН	6 Incarcerated
2 Hospital inpatient	Fac	ility ID:	7 Other (specify):
Facility ID:	5 🗌 Hon	neless	9 🗌 Unknown
3 🗌 LTCF	_		—
Facility ID:			
33. Was the patient in an ICU i	n the 14 days before, n	ot including the DISC?	
1 🗌 Yes 0 🗌 No 9 🗌 Unk	known		
34. Was the patient in an ICU o 1 Yes 0 No 9 Unk	-	pecimen collection or in the 1	.3 days after the DISC?
	CIOWII		
35. Did the patient receive inva	asive mechanical ventil	ation in the 30 days before th	e DISC, not including the DISC?
1 🗌 Yes 0 🗌 No 9 🗌 Unk	known		
26 Did the nationt receive dia		ont thorony (DDT) in the 20 d	ave before the DISC not including the DISC2
36. Did the patient receive dia 1Yes 0No 9Unk		ент шегару (ккт) in the 30 d	ays before the DISC, not including the DISC?

State ID: Date of In	cident Specimen Collection (<i>mm-dd-</i>	yyyy): Surveillance Officer Initials
37. Patient outcome: 1 Survived	9 Unknown 2	Died
Date of discharge:	Da	te of death:
	7	
	Unknown	Ulnknown
Left against medical advice (AMA)		
37a. Discharged to:		
0 🗌 Not applicable (i.e. patient died, or no		
1 Private residence	6 🗌 Homeless	
2 LTCF Facility ID:	7 Incarcerated	
3 LTACH Facility ID:	9 🗌 Unknown	
	Ilowing classes or specific ICD-10 co Jnknown	des, including any sub-codes for this hospitalization?
B37 (candidiasis)	B48 (other mycoses, not cla	assified elsewhere) 🗌 A41.9 (sepsis, unspecified organism)
Specify sub-code:		R65.2 (severe sepsis)
Specify sub-code:		
		Specify code:
P37.5 (neonatal candidiasis)		
39. Previous Hospitalization in the <u>90</u>	days before, not including the DISC:	: 1 🗌 Yes 0 🗌 No 9 🗌 Unknown
39a. If yes, date of discharge:	Unknown	
Facility ID:		
 40. Overnight stay in LTACH in the <u>9</u> Facility ID: 41. Overnight stay in LTCF in the <u>90</u> Facility ID: 		
UNDERLYING CONDITIONS 42. Underlying conditions (<i>Check all</i>	that apply): None Unkno	wn
Chronic Lung Disease	Liver Disease	Plegias/Paralysis
	Chronic Liver Disease	Hemiplegia
Chronic Pulmonary disease	Ascites	
Chronic Metabolic Disease	Cirrhosis	
	Hepatitis B, chronic	Lowest serum creatinine:mg,
CVA/Stroke/TIA	Treated, in SVR	
Congestive Heart Failure		
	Hepatitis B, acute	Decubitus/Pressure Ulcer
Peripheral Vascular Disease (PVD)	Malignancy	Surgical Wound
Gastrointestinal Disease	Malignancy, Hematologic	Other chronic ulcer or chronic wound
Diverticular disease	Malignancy, Solid Organ (non-r	metastatic) Other (specify):
Inflammatory Bowel Disease	Malignancy, Solid Organ (meta	
Peptic Ulcer Disease	Neurologic Condition	Connective tissue disease
Short gut syndrome		Obesity or morbid obesity
Immunocompromised Condition	Chronic Cognitive Deficit	Pregnant
$\square HIV infection$		or
□AIDS/CD4 count <200 □Primary Immunodeficiency	Epilepsy/seizure/seizure disord	
Transplant, Hematopoietic Stem Cell		
Transplant, Solid Organ	\square Parkinson's disease	
	Other (specify):	
SOCIAL HISTORY		
43. Smoking (Check all that apply):	44. Alcoh	ol Abuse:
Version: Short Form 2021	Last Updated: 07/2	Page 4 of 8
	0 paatoa. 0//2	,

State ID:	_ Date of Incident Specimen Colle	ection (<i>mm-dd-yyyy</i>):	Surveillance Officer Initials
None	Tobacco	1 🗌 Yes	
	E-nicotine delivery system	0 🗌 No	
		9 🗌 Unknown	
45. Other Substances (Ch	neck all that apply):	Unknown	
+J. Other Substances (Ch			<u>B. Mode of Delivery (Check all that apply):</u>
Marijuana (other than smo		DUD or abuse	IDU Skin popping Non-IDU Unknown
Opioid, DEA schedule I (e		DUD or abuse	□ IDU □Skin popping □Non-IDU □Unknown
Opioid, DEA schedule II-I	V (e.g., methadone, oxycodone)	DUD or abuse	IDU Skin popping Non-IDU Unknown
□Opioid, NOS		DUD or abuse	□IDU □Skin popping □Non-IDU □Unknown
		DUD or abuse	□IDU □Skin popping □Non-IDU □Unknown
Methamphetamine		DUD or abuse	DIDU Skin popping Non-IDU Unknown
_ (1 //		DUD or abuse	IDU Skin popping Non-IDU Unknown
Unknown substance		DUD or abuse	IDU Skin popping Non-IDU Unknown
46. During the current ho	ospitalization, did the patient rece	ive medication-assisted tre	eatment (MAT) for opioid use disorder?
1	8 N/A (patient not hospitalized or	r did not have DUD) 9	Unknown
OTHER CONDITIONS			
47. For cases \leq 1 year of	age: Gestational age at birth:	wks 9 🗌 Unknown A	ND Birth weight: gms 9 🗌 Unknown
48. Chronic Dialysis:	Not on chronic dialysis 🗌 Unknow	wn 46a. If Hemodialysis, ty	ype of vascular access:
Type: 🗌 Hemodialysis [Peritoneal	AV fistula/graft	Hemodialysis central line
-	ays before, not including the DIS	C: 50. Pancreatitis in th	ne <u>90 days before,</u> not including the DISC:
Abdominal surgery (specif	ý):	1 🗌 Yes	
If yes: 1 Open abdom	nen 0 🗌 Laparoscopic 9 🗌 Unknor	wn 0 🗌 No	
Non-abdominal surgery (s	pecify):	9 🗌 Unknown	
□No surgery			
51. Chronic Urinary Tract	Problems/Abnormalities:		patient have any urinary tract procedures in the 90
1 🗌 Yes 🛛 🗌 No	9 🗌 Unknown	days before, not incl 1 □Yes 0 □No	9 Unknown
E2. Was the nationt nout	rononic in the 2 colondar days had		
	ropenic in the 2 calendar days bef Unknown (no WBC days -2 or 0, or		- f
	a CVC in the 2 calendar days befor	,	
-	Had CVC but can't find dates 9		
	tral line in place for > 2 calendar days	_	
53a. If yes, CVC type: (<i>Chec</i>			
Non-tunneled CVCs	Implantable p	orts	Other (specify):
		serted central catheter (PICC)	
_	or changed on the day of or in the 6	. ,	
			9 🗌 Unknown
1	3 CVC removed, but can't f		
54. Did the patient have a	a midline catheter in the 2 calenda	- ·	ng the DISC?
	any of the following indwelling de	vices or other devices pres	ent in the 2 calendar days before, not including the
Urinary Catheter/Device			
			Abdominal drain (specify):
		ostomy	
		e mechanical ventilation	

State ID: D	Date of Incident Specimen Collection	(<i>mm-dd-yyyy</i>): Surveillance Officer	Initials
	ositive SARS-CoV-2 test result (mole ore the DISC or on the DISC?	cular assay, serology, or other confirmatory test) from	a specimen
1 🗌 Yes 0 🗌 No 9 🗍	Unknown		
56a. If yes, date of specimen co	ellection for initial positive SARS-CoV-2 tes	st:	
Date: 9 🗌 Date U			
56b. If yes, EIP COVID-NET Ca	se ID: 9 🗌 Unknown	Out of EIP COVID-NET catchment area	
		the 14 days before, not including the DISC?	
1 Yes 0 No 9 Unkno	- own		
58. Did the patient receive a	iny systemic steroids in the 30 days	before, not including the DISC?	
1 Yes 0 No 9 Unkno			
58a. If yes, what was the reaso	n steroids were administered? (check all a	that apply)	
.,-	n outpatient medication ng hospitalization associated with candide art of treatment/management for COVID-		
59. Did the patient receive t	otal parenteral nutrition (TPN) in the	e 14 days before, not including the DISC?	
1 Yes 0 No 9 Unkno	own		
60. Did the patient receive a all that apply)	any of the following immunomodula	tory drugs in the 30 days before the DISC, not including	g the DISC? (check
None Tocilizumab	Sarilumab Baricitinib	Unknown	
	nmunomodulatory drugs given as part of †]Unknown	treatment/management for COVID-19?	
61. Did the patient receive s	systemic antifungal medication on th	e day of or in the 13 days before the DISC?	
1 Yes (if Yes, fill out question)	<i>n 60)</i> 0 □No 9 □Unknown		
62. Was the patient adminis	tered systemic antifungal medicatio	n after, not including the DISC?	
1 🗌 Yes <i>(if Yes, fill out question</i>	<i>n 60)</i> 0 ⊡No 9 ⊡Unknown		
63. If antifungal medication	was not given to treat current cand	idemia infection, what was the reason?	
1 Patient died before culture	result available to clinicians	5 Other reason documented in medical records, specify:	
2 Comfort care only measure	s were instituted	6 Patient refused treatment against medical advice	
3 Patient discharged before c	ulture result available to clinician	9 🗌 Unknown	
4 Medical records indicated contaminated	ulture result not clinically significant or		
	IF ANY ANTIFUNGAL MEDICAT	ION WAS GIVEN, COMPLETE NEXT PAGE	
	that the incident specimen was cons	idered a contaminant or was considered to not be indica	ative of true of
infection? 1 □ Yes 0 □ No 9 □ 1	Unknown		
		ician on the day of the DISC or within the 6 days after t	he DISC2
	Unknown		
	UNKNOWN		
Version: Short Form 202	1 Last Upc	lated: 07/21/2020	Page 6 of 8

cet, AmBio ulafungin (any IV formulation (Amphotec, Amphoci some, etc.)=AMBIV Eraxis)=ANF ancidas)=CAS	FI Is It	uconazole (Diflucan)=FLC ucytosine (5FC)=5FC avuconazole (cresemba)=ISU raconazole (Sporanox)=ITC icafungin (Mycamine)=MFG	Po	ther=OTH bsaconazole (Noxafil)=PSC NKNOWN DRUG=UNK briconazole (Vfend)=VRC	
ANTIFUN a. Drug Abbrev	GAL MEDICATION b. First date given (<i>mm-dd-yyyy</i>)	c. Date start unknown	d. Last date given (<i>mm-dd-yyyy</i>)	e. Date stop unknown	f. Indication	g. Reason for stoppin (if applicable)*
	·				Prophylaxis	
			·		Prophylaxis	
	·		·		Prophylaxis	
			·		Prophylaxis	
			·		Prophylaxis	
			·		Prophylaxis	
					Prophylaxis	
					Prophylaxis	
	·				Prophylaxis	
					Prophylaxis	

State ID: ______ Date of Incident Specimen Collection (*mm-dd-yyyy*): ______ Surveillance Officer Initials ______

-----END OF CHART REVIEW FORM------

Version: Short Form 2021

Г

٦

tifungal cucconti	hility tosting (sh	AFST results for a		
Date of culture	Species	eck here 🗌 if no testing do Drug	MIC	Interpretation
Date of culture		Amphotericin B	MIC	
	1 ∐CA 2 □CG	Anidulafungin (Eraxis)		
	3 □CP	Caspofungin (Cancidas)		S
	4 □CT 5 □CD	Fluconazole (Diflucan)		
	6 🗌 CL	Flucytosine (5FC)		
	7 🗌 СК 8 🗍 С G М	Itraconazole (Sporanox)		
	9 🗌 CO	Micafungin (Mycamine)		
	10 □CGN 11 □CS	Posaconazole (Noxafil)		
	11 CS 12 Pending	Voriconazole (Vfend)		
		Amphotericin B		
	1 □CA 2 □CG	Anidulafungin (Eraxis)		
	3 CP	Caspofungin (Cancidas)		
	4 □CT	Fluconazole (Diflucan)		
	5 🗌 CD 6 🔲 CL	Flucytosine (5FC)		
	7 🗌ск	Itraconazole (Sporanox)		
	8 🗌 С G M 9 🔲 С O			
	10 CGN	Micafungin (Mycamine)		
	11 🗆 CS	Posaconazole (Noxafil)		
	12 Pending	Voriconazole (Vfend)		S SDD I R NI ND
Date of culture	bility testing (che Species	eck here 🗌 if no testing do Drug	ne/no test re MIC	ports available): Interpretation
	_	Amphotericin B	Міс	
	1 □CA 2 □CG	Anidulafungin (Eraxis)		
	3 🗌 СР	Caspofungin (Cancidas)		
	4 □CT 5 □CD	1 3 ()		
	6 []CL	Fluconazole (Diflucan)		
	7 □ск	Flucytosine (5FC)		
	8 🗌 CGM	Itraconazole (Sporanox)		
	9 □CO 10 □CGN	Micafungin (Mycamine)		S SDD I R NI ND
	10 □CGN 11 □CS	Posaconazole (Noxafil)		S SDD I R NI ND
	10 🗌 CGN	Posaconazole (Noxafil) Voriconazole (Vfend)		S SDD I R NI IND S SDD I R INI IND S SDD I R INI IND S SDD I R INI IND
	10 CGN 11 CS 12 Pending 1 CA	Posaconazole (Noxafil) Voriconazole (Vfend) Amphotericin B		S SDD I R NI ND
	10 CGN 11 CS 12 Pending 1 CA 2 CG	Posaconazole (Noxafil) Voriconazole (Vfend) Amphotericin B Anidulafungin (Eraxis)		S SDD I R NI ND
	10 CGN 11 CS 12 Pending 1 CA	Posaconazole (Noxafil) Voriconazole (Vfend) Amphotericin B Anidulafungin (Eraxis) Caspofungin (Cancidas)		S SDD I R NI ND S SDD I R NI ND
	10 CGN 11 CS 12 Pending 1 CA 2 CG 3 CP 4 CT 5 CD	Posaconazole (Noxafil) Voriconazole (Vfend) Amphotericin B Anidulafungin (Eraxis)		S SDD I R NI ND
	10 CGN 11 CS 12 Pending 1 CA 2 CG 3 CP 4 CT 5 CD 6 CL	Posaconazole (Noxafil) Voriconazole (Vfend) Amphotericin B Anidulafungin (Eraxis) Caspofungin (Cancidas)		S SDD I R NI ND S SDD I R NI ND
	10 CGN 11 CS 12 Pending 1 CA 2 CG 3 CP 4 CT 5 CD	Posaconazole (Noxafil) Voriconazole (Vfend) Amphotericin B Anidulafungin (Eraxis) Caspofungin (Cancidas) Fluconazole (Diflucan)		SSDDIRNINDSSDDIRNINDSSDDIRNINDSSDDIRNINDSSDDIRNINDSSDDIRNINDSSDDIRNINDSSDDIRNINDSSDDIRNINDSSDDIRNIND
	10 CGN 11 CS 12 Pending 1 CA 2 CG 3 CP 4 CT 5 CD 6 CL 7 CK 8 CGM 9 CO	Posaconazole (Noxafil) Voriconazole (Vfend) Amphotericin B Anidulafungin (Eraxis) Caspofungin (Cancidas) Fluconazole (Diflucan) Flucytosine (5FC)		SSDDIRNINDSSDDIRNINDSSDDIRNINDSSDDIRNINDSSDDIRNINDSSDDIRNINDSSDDIRNINDSSDDIRNINDSSDDIRNINDSSDDIRNINDSSDDIRNINDSSDDIRNIND
	10 CGN 11 CS 12 Pending 1 CA 2 CG 3 CP 4 CT 5 CD 6 CL 7 CK 8 CGM	Posaconazole (Noxafil) Voriconazole (Vfend) Amphotericin B Anidulafungin (Eraxis) Caspofungin (Cancidas) Fluconazole (Diflucan) Flucytosine (5FC) Itraconazole (Sporanox)		SSDDIRNINDSSDDIRNINDSSDDIRNINDSSDDIRNINDSSDDIRNINDSSDDIRNINDSSDDIRNINDSSDDIRNINDSSDDIRNINDSSDDIRNINDSSDDIRNINDSSDDIRNINDSSDDIRNIND